单次19 Gy高剂量率近距离放疗II期试验的复发模式与剂量学分析
该前瞻性II期研究纳入44例接受单次19 Gy高剂量率近距离放疗的前列腺癌患者,中位随访48个月,14例(32%)出现生化失败。剂量学分析显示生化失败组V100、V125和D90显著更低,提示存在剂量-反应关系。中危、mpMRI可见优势前列腺内病灶及植入较冷的患者生化和局部失败率更高。
要点
- 单次19 Gy HDR近距离放疗后中位48个月随访,生化失败率为32%。
- 生化失败组V100、V125和D90剂量参数显著更低,提示剂量-反应关系。
- 中危、mpMRI可见DIL及植入较冷的患者生化和局部失败率更高。
核心结论
- 单次19 Gy HDR近距离放疗存在剂量-反应关系,中危、可见DIL及植入较冷的患者生化和局部失败率更高。
研究设计与样本
- 前瞻性II期研究,44例前列腺癌患者接受单次19 Gy HDR近距离放疗,中位随访48个月(范围29-63)。
主要发现
- 14例(32%)出现生化失败,其中低危4例、中危10例(p=0.013)。
- 11/14例患者再分期mpMRI,11例经MRI-TRUS融合活检证实局部复发。
- 生化失败组V100、V125和D90显著更低(p=0.032、p=0.018、p=0.018)。
- 在诊断性mpMRI可见DIL的患者中,生化失败组DIL的平均D90和D98更低。
- PSA最低点出现在24个月随访时,中位值为1.07 ng/mL。
临床怎么用
- 对于中危、mpMRI可见DIL的患者,应关注剂量覆盖,避免植入较冷导致生化失败风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the pattern of relapse within the prostate with reference to the initial site of disease in patients treated with single fraction 19-Gy. METHODS AND MATERIALS: Forty-four patients were treated according to a prospective study of single-fraction HDR-brachytherapy. Treatment was delivered using 192Ir to a dose of 19 Gy prescribed to the prostate. Patients who experienced a biochemical failure underwent a re-staging multiparametric MRI (mpMRI) and MRI-TRUS fusion biopsy to rule-out local recurrence. In patients with visible Dominant intraprostatic lesions (DIL) on pretreatment mpMRI, the site of local relapse was compared with the initial site of disease. The dose received by the site of recurrence was investigated. RESULTS: The median follow-up period was 48 months (range 29-63). The PSA nadir was reached at 24 months follow-up, with a median value of 1.07 ng/mL. To date, 14 patients (32%) have experienced biochemical failure (4 patients low-risk and 10 intermediate-risk; p = 0.013). Re-staging mpMRI was performed in 11/14 patients. Eleven patients underwent MRI-TRUS fusion biopsy confirming local relapse in all patients. The analysis of DVH of all 44 patients revealed that patients with biochemical failure had received significantly lower doses in terms of V100, V125 and D90 (p = 0.032, p = 0.018 and p = 0.018 respectively). In patients with DILs on diagnostic mpMRI, the mean D90 and D98 on DIL were lower for patients with biochemical failure. CONCLUSIONS: This dosimetric analysis demonstrates a dose-response relationship in patients treated with single fraction 19 Gy. Patients with intermediate risk disease, with visible DIL on mpMRI and patients treated with cooler implants have higher incidence of biochemical and local failure.
引用
- Gomez-Iturriaga A, Buchser D, Mayrata E, et al. Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial. Radiother Oncol. 2020. PMID: 32086047. doi:10.1016/j.radonc.2020.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。